Validation and Performance of FibroScan®-AST (FAST) Score on a Brazilian Population with Nonalcoholic Fatty Liver Disease

Autor: Ana Carolina Cardoso, Cristiane Valle Tovo, Nathalie Carvalho Leite, Ibrahim A. El Bacha, Fernanda Luiza Calçado, Gabriela Perdomo Coral, Glauco Navas Sammarco, Claudia Cravo, Roberto José Carvalho Filho, Renata de Mello Perez, Ronir Raggio Luiz, Edison Roberto Parise, Cristiane A. Villela-Nogueira
Rok vydání: 2022
Předmět:
Zdroj: Digestive Diseases and Sciences. 67:5272-5279
ISSN: 1573-2568
0163-2116
DOI: 10.1007/s10620-021-07363-x
Popis: FAST score has a good performance for diagnosing the composite of NASH + NAS ≥ 4 + F ≥ 2. However, it has not been evaluated in Latin American individuals with nonalcoholic fatty liver disease (NAFLD). We aimed to analyze the performance of the FAST score in a Brazilian NAFLD population.Cross-sectional study was held in ≥ 18 years NAFLD patients diagnosed by ultrasonography and submitted to liver biopsy (LB). Liver stiffness (LSM) and CAP measurements were performed with FibroScan®, using M (BMI 32 kg/mAmong 287 patients included (75% female; mean age 55 ± 10 years), NASH + NAS ≥ 4 + F ≥ 2 was reported in 30% of LB. For the FAST cut-off of 0.35, the S and NPV to rule out NASH + NAS ≥ 4 + F ≥ 2 were 78.8% and 87.8%, respectively. Regarding the cut-off of 0.67, the Spe and PPV to rule-in NASH + NAS ≥ 4 + F ≥ 2 were 89.1%, 61.8%, respectively. The AUROC of FAST for all included patients was 0.78 (95% CI 0.72-0.84) and for those with ≥ 32 kg/mFAST score has a good performance in a Brazilian NAFLD population, even in patients with higher BMI when the XL probe is adopted. Therefore, FAST can be used as a noninvasive screening tool mainly for excluding the diagnosis of progressive NASH, reducing the number of unnecessary liver biopsies.
Databáze: OpenAIRE
Externí odkaz: